Philadelphia, Pennsylvania--(Newsfile Corp. - February 23, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Varonis Systems, Inc. (NASDAQ: VRNS) ("Varonis" or the "Company") on behalf of investors who purchased or otherwise acquired Varonis securities during the period of February 4, 2025 through October 28, 2025 (the "Class Period").Investor Deadline: Investors who purchased Varonis securities during the Class Period may, no later than M ...

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab for treating Osteogenesis Imperfecta [1][3]. Company Overview - Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [2]. Allegations of the Lawsuit - The lawsuit claims that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects on patients and downplayed the risks associated with the Phase III Orbit study, which ultimately failed to show statistically significant results [3]. - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [4]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ultragenyx common stock during the class period to seek appointment as lead plaintiff, representing the interests of the class [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years [7].

Core Points - The Corcept Therapeutics class action lawsuit seeks to represent investors who purchased common stock between October 31, 2024, and December 30, 2025, alleging violations of the Securities Exchange Act of 1934 [1] - The lawsuit claims that Corcept misrepresented the support for its relacorilant New Drug Application (NDA), suggesting it was close to FDA approval despite known concerns from the FDA regarding clinical evidence [1] - On December 31, 2025, Corcept disclosed that the FDA issued a Complete Response Letter (CRL) for the relacorilant NDA, leading to a more than 50% drop in the company's stock price [1] - The FDA's CRL indicated that the clinical studies submitted were insufficient to demonstrate relacorilant's efficacy, and the FDA had previously warned Corcept about significant review issues [1] Company Overview - Corcept Therapeutics is engaged in the discovery and development of medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders, with relacorilant being a lead candidate for treating hypercortisolism [1] - The company has faced significant scrutiny regarding the adequacy of its clinical development program for relacorilant, which has implications for its future product approvals and market performance [1] Legal Context - The Private Securities Litigation Reform Act of 1995 allows investors who suffered losses during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [1] - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [1]

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of NuScale Power Corporation (NYSE: SMR) Class A common stock between May 13, 2025 and November 6, 2025, both dates inclusive (the “Class Period”), have until April 20, 2026 to seek appointment as lead plaintiff of the NuScale class action lawsuit. Captioned Truedson v. NuScale Power Corporation, No. 26-cv-00328 (D. Or.), the NuScale class action lawsuit charges NuScale, certain NuScale top executive offi ...

Core Viewpoint - Kyndryl Holdings, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading financial statements and inadequate internal controls during the specified class period [1][3]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled Brander v. Kyndryl Holdings, Inc., and it allows purchasers of Kyndryl securities from August 7, 2024, to February 9, 2026, to seek lead plaintiff status by April 13, 2026 [1][5]. - The lawsuit alleges that Kyndryl's financial statements were materially misstated and that the company lacked adequate internal controls, which led to an inability to timely file its Quarterly Report for the quarter ended December 31, 2025 [3][4]. Financial and Operational Implications - On February 9, 2026, Kyndryl announced it would be unable to file its Quarterly Report on Form 10-Q on time, citing a review of its cash management practices and internal controls following SEC inquiries [4]. - The company anticipates reporting material weaknesses in its internal control over financial reporting for the fiscal year ended March 31, 2025, and the first two quarters of fiscal year 2026 [4]. - Following the announcement, Kyndryl's stock price fell by 55% [4]. Company Background - Kyndryl operates as a technology services company and IT infrastructure services provider [2]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6].

Core Viewpoint - Halper Sadeh LLC is investigating the sale of Arcellx, Inc. to Gilead Sciences, Inc. for $115.00 per share in cash, plus a contingent value right of $5.00 per share based on certain milestones [1] Group 1: Investigation Details - The investigation focuses on whether Arcellx and its board violated federal securities laws and/or breached fiduciary duties by failing to obtain the best possible price for shareholders [2] - Concerns include the fairness of the sales process and potential conflicts of interest, as well as the adequacy of disclosed material information for shareholders to evaluate the transaction [2] Group 2: Potential Actions - Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief and benefits on behalf of shareholders [3] - The firm represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [3]

Core Viewpoint - A class action lawsuit has been filed against NuScale Power Corporation and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Oregon, captioned Truedson v. NuScale Power Corporation, et al., No. 3:26-cv-00328 [3]. - Investors have until April 20, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - NuScale Power Corporation specializes in nuclear technology, particularly the NuScale Power Module (NPM), a small modular nuclear reactor designed for energy generation [4]. - The company had established a partnership with ENTRA1 Energy LLC, which was responsible for constructing power generation facilities using NuScale's NPMs [4]. Group 3: Allegations Against ENTRA1 - NuScale allegedly misrepresented ENTRA1's capabilities, claiming it had extensive experience in developing power plants, while in reality, ENTRA1 had never built or operated any significant projects [5][6]. - ENTRA1 was primarily organized to support the activities of its principal, Wadie Habboush, rather than to undertake substantial projects [6]. Group 4: Stock Price Impact - On November 6, 2025, NuScale reported a dramatic increase in general and administrative expenses from $17 million in the prior year to $519 million in 3Q 2025, largely due to a $495 million payment to ENTRA1 [7]. - Following the disclosure of ENTRA1's lack of experience in nuclear power projects, NuScale's stock price fell by $4.03 per share, a decline of over 12.4%, from $32.46 on November 6, 2025, to $28.43 on November 10, 2025 [7].

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to be appointed to lead the case [3]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Ardent Health securities [3]. Group 2: Allegations Against Ardent Health - Ardent Health operates acute care hospitals and healthcare facilities, with a critical focus on the collection of accounts receivable [4]. - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections," while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health disclosed a $43 million revenue decrease for the quarter due to "hindsight evaluations of historical collection trends" and increased its professional liability reserves by $54 million [5]. - Following this announcement, Ardent Health's stock price fell by $4.75 per share, a decline of over 33%, from $14.05 to $9.30 per share [5].

Core Viewpoint - A class action lawsuit has been filed against Plug Power Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of New York, captioned Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165 [3]. - Investors have until April 3, 2026, to request to be appointed to lead the case [3]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Plug Power securities [3]. Group 2: Company Background - Plug Power provides hydrogen fuel cell turnkey solutions for electric mobility and stationary power markets and develops infrastructure such as hydrogen production plants [4]. - The company announced a "closed a $1.66 billion loan guarantee" from the U.S. Department of Energy to finance the construction of hydrogen production projects [4]. Group 3: Stock Performance and Events - On October 7, 2025, Plug Power's stock dropped by $0.26 per share (6.3%) following the abrupt departure of its CEO and President, from $4.13 to $3.87 [5]. - On November 10, 2025, the company announced the suspension of activities under the DOE loan program, leading to a stock drop of $0.09 per share (3.4%), from $2.65 to $2.56 [6]. - A report on November 13, 2025, confirmed the suspension of plans to construct hydrogen production facilities, resulting in a stock drop of $0.48 per share (17.6%), from $2.49 to $2.25 [7].

Core Viewpoint - Ralliant Corporation is under investigation for potential violations of federal securities laws, particularly regarding the timing and disclosure of financial information related to a significant goodwill impairment and reduced earnings guidance [1][6]. Financial Performance and Guidance - On January 30, 2026, Ralliant announced a $1.4 billion goodwill impairment and lowered its FY 2026 earnings guidance to a range of $2.22 to $2.42 per share, which was below analyst consensus expectations [2][3]. - The guidance indicated that factors such as declining demand and competitive pressures would negatively impact performance beyond the fourth quarter, raising concerns about the company's financial health [3][4]. Dividend Declaration - Just five days prior to the impairment announcement, Ralliant's board declared a quarterly dividend of $0.05 per share, which is typically seen as a sign of financial stability and management confidence [2]. - The decision to declare a dividend amidst a significant loss has led to questions regarding the board's assessment of the company's financial position at that time [2][6]. Institutional Trading Activity - STRS Ohio significantly reduced its stake in Ralliant by 95.6%, involving approximately 58,434 shares, just days before the earnings release, which has drawn scrutiny regarding the timing of trading decisions [5]. - The timing of this liquidation raises questions about whether institutional investors had prior knowledge of the company's deteriorating outlook [5]. Investigation Focus - The investigation will assess whether Ralliant and its executives disclosed all material facts about the company's outlook in a timely manner and whether their forward-looking statements were consistent with their knowledge at the time [6].